Background The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-
1The lower and upper bounds reflect probabilities for CD4 cell counts of >500 cells/µL and 0–50 cells/µL, respectively.2Expert opinion (2009).3Costs vary by CD4 cell count, HAART usage, and history of
